CBOA
VRTX icon

Commonwealth Bank of Australia’s Vertex Pharmaceuticals VRTX Stock Holding History

Commonwealth Bank of Australia’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-3,427
Closed -$626K – 926
2019
Q2 		$626K Buy
3,427
+721
+27% +$126K 0.01% 659
2019
Q1 		$496K Buy
2,706
+183
+7% +$33.8K ﹤0.01% 641
2018
Q4 		$415K Buy
2,523
+163
+7% +$28.2K ﹤0.01% 641
2018
Q3 		$453K Buy
2,360
+28
+1% +$4.99K ﹤0.01% 688
2018
Q2 		$395K Buy
2,332
+132
+6% +$20.5K ﹤0.01% 600
2018
Q1 		$357K Sell
2,200
-459
-17% -$75K ﹤0.01% 565
2017
Q4 		$395K Sell
2,659
-155
-6% -$22.9K ﹤0.01% 562
2017
Q3 		$425K Sell
2,814
-718
-20% -$108K ﹤0.01% 573
2017
Q2 		$453K Buy
3,532
+190
+6% +$22.9K ﹤0.01% 591
2017
Q1 		$365K Buy
3,342
+2,381
+248% +$210K ﹤0.01% 594
2016
Q4 		$71K Buy
961
+145
+18% +$11.8K ﹤0.01% 707
2016
Q3 		$71K Hold
816
– – ﹤0.01% 701
2016
Q2 		$71K Buy
816
+90
+12% +$7.78K ﹤0.01% 680
2016
Q1 		$58K Buy
726
+190
+35% +$17.2K ﹤0.01% 735
2015
Q4 		$67K Buy
536
+190
+55% +$22.9K ﹤0.01% 714
2015
Q3 		$36K Buy
346
+11
+3% +$1.41K ﹤0.01% 785
2015
Q2 		$41K Buy
335
+35
+12% +$4.41K ﹤0.01% 729
2015
Q1 		$35K Hold
300
– – ﹤0.01% 735
2014
Q4 		$36K Sell
300
-6,000
-95% -$676K ﹤0.01% 713
2014
Q3 		$708K Sell
6,300
-400
-6% -$38.1K 0.01% 539
2014
Q2 		$634K Sell
6,700
-116,732
-95% -$8.19M 0.01% 546
2014
Q1 		$8.73M Sell
123,432
-5,520
-4% -$437K 0.06% 320
2013
Q4 		$9.58M Buy
128,952
+40,078
+45% +$2.79M 0.07% 285
2013
Q3 		$6.74M Sell
88,874
-21,210
-19% -$1.69M 0.05% 332
2013
Q2 		$8.81M Buy
+110,084
New +$8.11M 0.07% 263

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Commonwealth Bank of Australia's VRTX Position: Q3 2019 in Review

Commonwealth Bank of Australia sold out of Vertex Pharmaceuticals (VRTX) in Q3 2019, closing a stake of 3,427 shares — an estimated $626K sold.

Commonwealth Bank of Australia first reported a position in VRTX in Q2 2013 and held it in 25 quarters. The position peaked at $9.58M in Q4 2013. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

  • Commonwealth Bank of Australia reported no remaining Vertex Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Commonwealth Bank of Australia sold 3,427 Vertex Pharmaceuticals shares in Q3 2019, an estimated $626K.
  • Commonwealth Bank of Australia first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 25 quarters.
  • Commonwealth Bank of Australia's Vertex Pharmaceuticals position peaked at $9.58M in Q4 2013.
  • 708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Commonwealth Bank of Australia's 13F filing for Q3 2019.